This inventor holds 3 USPTO granted patents and 1 published patent application. Top assignee: Biocardia, Inc.. Active years: 2013-2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Buenos Aires, AR (2013 - 2016)
- Buenos Aires, BR (2016)
Company Filing History:
Years Active: 2013-2016
Title: Innovations in Cardiac Treatment by Eduardo Penaloza
Introduction
Eduardo Penaloza is a notable inventor based in Buenos Aires, Argentina. He has made significant contributions to the field of cardiac treatment, particularly in the area of chronic myocardial infarction. With a total of 3 patents to his name, Penaloza's work is recognized for its innovative approaches to improving patient outcomes.
Latest Patents
One of Eduardo Penaloza's latest patents involves a method of treating chronic post-myocardial infarction. This treatment utilizes helical needle transendocardial delivery of autologous bone marrow (ABM) mononuclear cells around regions of hypo or akinesia in chronic post-myocardial infarction patients. The treatment has been shown to be safe and effective in improving ejection fraction (EF), which is crucial for the recovery of heart function.
Career Highlights
Penaloza is currently associated with Biocardia, Inc., where he continues to develop and refine his innovative treatment methods. His work has garnered attention for its potential to significantly enhance the quality of life for patients suffering from heart conditions.
Collaborations
Throughout his career, Eduardo Penaloza has collaborated with esteemed colleagues such as Luis M De La Fuente and Simon H Stertzer. These partnerships have further enriched his research and development efforts in the medical field.
Conclusion
Eduardo Penaloza's contributions to cardiac treatment through his innovative patents highlight the importance of research and development in improving healthcare outcomes. His work continues to inspire advancements in the treatment of chronic myocardial infarction.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile